Document:

dmtk-ex105_132.htm

Exhibit 10.5

AMENDMENT NUMBER 2 TO THE DEFERRED UNDERWRITING FEE ASSIGNMENT AGREEMENT

 

Cowen and Company, LLC

As Representative of the several Underwriters

c/o Cowen and Company, LLC

1221 Avenue of the Americas

New York, New York 10020

 

July 14, 2020

			
	
 
	
Re:
	
Deferred Underwriting Fee Assignment Agreement

 

Ladies and Gentlemen:

 

Reference is made to that certain Deferred Underwriting Fee Assignment Agreement, dated May 29, 2019, as amended by that certain Amendment Number 1 to the Deferred Underwriting Fee Assignment Agreement, dated September 4, 2019 (collectively, the “Fee Agreement”), by and among DermTech, Inc. (formerly known as Constellation Alpha Capital Corp.), a Delaware corporation (“DermTech”), DermTech Operations, Inc. (formerly known as DermTech, Inc.), a Delaware corporation (“DermTech Operations”), and Cowen and Company, LLC (“Cowen”), acting as representative of the underwriters (the “Underwriters”) named in Schedule A to that certain Underwriting Agreement, dated as of June 19, 2017.  Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Fee Agreement.  

 

Cowen, DermTech, and DermTech Operations hereby agree to amend the Fee Agreement as follows:

 

	
 
	
1.
	
 Paragraph 5 is hereby amended and restated in its entirety as follows:

 

“If, during the eighteen (18) month period following the Closing, the Company proposes to effect any restructuring transaction (through a recapitalization, extraordinary dividend, stock repurchase, spin-off, joint venture or otherwise), any acquisition or disposition transaction (including, without limitation, a merger, exchange offer, sale or purchase of assets or capital stock), any bank financing for aggregate proceeds to the Company of more than $25,000,000 in a single transaction, any public offering, any Rule 144A offering or any private placement of securities, the Company agrees to offer to engage Cowen as the Company’s exclusive financial advisor, lead lender or arranger, lead manager underwriter, lead purchaser, or exclusive placement agent, as the case may be, in connection with such transaction(s) on terms and conditions customary to investment banks for similar transactions; provided, however, that Cowen may decline in writing such engagement in its sole and absolute discretion.  The terms of such engagements shall be set forth in separate agreements and may be subject to, among other things, satisfactory completion of due diligence by Cowen, market conditions, the absence of adverse changes to the Company’s business or financial condition, approval of Cowen’s internal committee and any other conditions that Cowen may deem appropriate for transactions of such nature.”

 

All other terms and conditions of the Fee Agreement shall remain in full force and effect.

 

This Amendment Number 2 to the Fee Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York.  This Amendment Number 2 to the Fee Agreement may be executed and delivered (including by facsimile transmission or by electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

 

[Signature Pages Follow]

 

 

 

 

	
DERMTECH, INC.

	
 
	
 
	
 

	
By:
	
/s/ Kevin Sun

	
 
	
Name:
	
Kevin Sun

	
 
	
Title:
	
Chief Financial Officer

	
 
	
 
	
 

	
 
	
 
	
 

	
DERMTECH OPERATIONS, INC.

	
 
	
 
	
 

	
 
	
 
	
 

	
By:
	
/s/ Kevin Sun

	
 
	
Name: Kevin Sun

	
 
	
Title:
	
Chief Financial Officer

	
 
	
 
	
 

 

 

	
Acknowledged and Agreed: 
	
 

	
 
	
 

	
COWEN AND COMPANY, LLC
	
	
 
	
	
By:
	
/s/ Rob Weir 
	
	
 
	
Name: Rob Weir
	
	
 
	
Title: Managing Director
	

 

[Signature Page to Amendment Number 2 to Deferred Underwriting Fee Assignment Agreement]harp-ex101_27.htm

EXHIBIT 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

FIRST AMENDMENT TO THE

DEVELOPMENT AND OPTION AGREEMENT

 

This First Amendment (the “First Amendment”) to the Development and Option Agreement dated November 20, 2019 (the “Agreement”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”) is made effective as of the date of the final signature to this First Amendment.  Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”  

 

RECITALS

 

WHEREAS, AbbVie and Harpoon entered into the Agreement pertaining to the Development and Commercialization of certain Licensed Products; 

 

WHEREAS, Section 3.1.1 of the Agreement contemplates that the Parties shall amend the Initial Development Plan to include certain [***]; and

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows:

 

	
1.
	
Schedule 1.84 of the Agreement is deleted in its entirety and replaced with the Initial Development Plan attached hereto as Schedule A.

 

	
2.
	
Section 1.54 of the Agreement is amended to replace the reference to “Section 1.110” with “Section 1.111”.

 

	
3.
	
Sections 2.1.2(i) through 2.1.2(l) of the Agreement shall be renumbered as Sections 2.1.2(j) through 2.1.2(m), respectively.

 

	
4.
	
Section 2.1.2 of the Agreement is amended to insert the following as a new Section 2.1.2(i) 

 

“(i) review and approve any amendments to the [***], such JGC approval shall constitute amendment of [***] without amendment of this Agreement;”

 

	
5.
	
Except as specifically modified or amended hereby, the Agreement shall remain in full force and effect and, as modified or amended, is hereby ratified, confirmed and approved. Any capitalized terms not defined in this First Amendment shall have the meanings set forth in the Agreement.  This First Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. This First Amendment may be executed by facsimile or electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures. This First Amendment is the product of both of the Parties hereto and that, in the event of a dispute over its interpretation, the language of this First Amendment will not be construed against one Party in favor of the other. This First Amendment together with the Agreement constitutes the entire agreement between such Parties pertaining to the subject matter hereof, and merges all prior negotiations and drafts of the Parties with regard to the transactions contemplated herein. From the date hereof, any reference to the Agreement shall be deemed to refer to the Agreement as amended by this First Amendment.

 

 

 

[Signature Page Follows]

 

CONFIDENTIAL

 

[Signature Page to the First Amendment to the Development and Option Agreement]

 

 

IN WITNESS WHEREOF, each of the parties has caused this First Amendment to be executed by its authorized representative in its name and on its behalf.

 

HARPOON THERAPEUTICS, INC.ABBVIE BIOTECHNOLOGY LTD

 

By: /s/ Gerald McMahonBy:/s/ Stephen Muldoon

 

	
Name: 
	
Gerald McMahonName: Stephen Muldoon     

 

	
Title: 
	
President & CEOTitle: Director

 

Date: March 13, 2020Date: April 21, 2020

 

 

 

 

CONFIDENTIALharp-ex102_28.htm

 

 

EXHIBIT 10.2

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

April 15, 2020

AbbVie Biotechnology Ltd.

c/o Conyers, Dill & Pearman,

Clarendon House,

2 Church Street,

Hamilton HM 11 Bermuda 

AbbVie Inc.

1 North Waukegan Road

North Chicago, Illinois 60064 United States

Attention: [***]

Dear Sir or Madam:

Re: Amendment to Development and Option Agreement between Harpoon Therapeutics, Inc. (“Harpoon”) and AbbVie Biotechnology Ltd. (“AbbVie”).

We refer to the Development and Option Agreement between Harpoon and AbbVie dated November 20, 2019, pursuant to which Harpoon granted AbbVie an option to be granted an exclusive license under Harpoon’s relevant intellectual property rights to develop and commercialize Licensed Products in the Territory (each as defined therein) (the “Development and Option Agreement”).  Each capitalized term set forth in this letter (the “Letter Agreement”) shall have the meaning given to it in the Development and Option Agreement, unless otherwise defined herein.

As you are aware from the letter sent by Harpoon to AbbVie dated [***].  In particular, and as noted in our letter, because of [***].  Following further discussion between representatives of each of Harpoon and AbbVie, the Parties have agreed to [***].  

Accordingly, and in order to memorialize such understanding, the Parties hereby agree by this Letter Agreement to make the following amendment to the Development and Option Agreement:

Section 6.2.2 is hereby deleted, and replaced in its entirety with the following language: 

“6.2.2.upon [***], [***]; provided that subject to Section 3.1.3, (a) if [***], but [***], this milestone payment shall be [***], and (b) if such [***] occurs on or after [***], this milestone payment shall be [***].”  

Except for the foregoing amendment, the Development and Option Agreement shall remain unamended and in force in its entirety. 

 

2

 

 Each party will be responsible for and bear all of its own costs and expenses incurred in connection with the negotiation of this Letter Agreement.  This Letter Agreement shall be governed by the laws of the State of Delaware, United States, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Letter Agreement to the substantive law of another jurisdiction.  Section 13.7 of the Development and License Agreement shall apply to any disputes arising hereunder. This Letter Agreement, together with the Development and Option Agreement and the Prior NDA, constitutes the complete and exclusive agreement of the parties with respect to the subject matter hereof and thereof.  This Letter Agreement may not be modified except by a written instrument signed by both parties.  No failure or delay of one of the parties to insist upon strict performance of any of its rights or powers under this Letter Agreement shall operate as a waiver thereof, nor shall any other single or partial exercise of such right or power preclude any other further exercise of any rights or remedies provided by law.  This Letter Agreement may be executed in multiple counterparts (including by facsimile), each of which shall be deemed an original and all of which together shall constitute one and the same instrument.  

If this Letter Agreement is acceptable to you, please indicate your acceptance by countersigning this Letter Agreement below and returning a copy to Harpoon at the above address.  

Yours sincerely,

HARPOON THERAPEUTICS, INC.

	
By: /s/ Rachael Lester
	

	
Name: Rachael Lester
	

	
Title: VP Corporate Development 
	

ABBVIE BIOTECHNOLOGY LTD.

	
By: /s/ Stephen Muldoon
	

	
Name: Stephen Muldoon
	

Title:Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]